Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Next Previous
X
Search
Trial Profile

A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms STYLE
  • Sponsors Amgen; Celgene Corporation

    • Most Recent Events

    • 25 Apr 2021 Results of subgroup analyses of apremilast assessing the systemic treatment history in patients with moderate-to-severe plaque psoriasis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
    • 25 Apr 2021 Results of post hoc analysis of apremilast assessing the improvements in head scaling and head erythema PASI subscale scores in moderate-to-severe plaque psoriasis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
    • 04 Feb 2020 Results published in the Journal of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top